‚ª‚ñŽí•Ê@ƒŒƒWƒƒ“ˆê——@ | |||
‚¨’T‚µ‚̃ŒƒWƒƒ“‚ðƒuƒ‰ƒEƒU‚ÌŒŸõ‹@”\‚ÅŒŸõ‚µ‚Ä‚‚¾‚³‚¢B ‚ª‚ñ–¼Ì‚ðƒNƒŠƒbƒN‚·‚邯Še‚ª‚ñŽíƒŒƒWƒƒ“‚ÌÚ׃y[ƒW‚ɈÚs‚µ‚Ü‚·B |
|||
ƒgƒbƒv‚É–ß‚é | |||
MDS | ƒŒƒWƒƒ“–¼ | ||
@ | yS.C.zƒrƒ_[ƒU’P“ÆŽ¡—Ã | ||
‘½”«œ‘Žî | ƒŒƒWƒƒ“–¼ | ||
@ | yS.C.zBDiƒxƒ‹ƒPƒCƒh”牺’+ƒfƒLƒTƒƒ^ƒ]ƒ“j | ||
@ | yS.C.zVRDа‰ð“±“üƒxƒ‹ƒPƒCƒh”牺’{ƒŒƒuƒ‰ƒ~ƒh{ƒfƒLƒTƒƒ^ƒ]ƒ“ | ||
@ | DLd(1ƒTƒCƒNƒ‹) | ||
@ | DLdi2ƒTƒCƒNƒ‹) | ||
@ | DLdi3`6ƒTƒCƒNƒ‹j | ||
@ | DLdi7ƒTƒCƒNƒ‹ˆÈ~) | ||
@ | Eld(1`2ƒTƒCƒNƒ‹) | ||
@ | Eldi3ƒTƒCƒNƒ‹ˆÈ~j | ||
@ | KRdi2`12ƒTƒCƒNƒ‹) | ||
@ | VMPа‰ð“±“üiƒxƒ‹ƒPƒCƒh”牺’j | ||
@ | VMPˆÛŽiƒxƒ‹ƒPƒCƒh”牺’j | ||
@ | KDi2ƒTƒCƒNƒ‹ˆÈ~) | ||
@ | PBD—Ö@i1`8ƒTƒCƒNƒ‹–Új | ||
@ | PBD—Ö@i9ƒTƒCƒNƒ‹–ÚˆÈ~j | ||
@ | weekly KD—Ö@i1ƒTƒCƒNƒ‹–Új | ||
@ | yƒVƒ‡[ƒgzweekly KD—Ö@i2ƒTƒCƒNƒ‹ˆÈ~j | ||
@ | EPDi1ƒTƒCƒNƒ‹j | ||
@ | EPDi2ƒTƒCƒNƒ‹j | ||
@ | EPDi3ƒTƒCƒNƒ‹j | ||
@ | EPDi4ƒTƒCƒNƒ‹ˆÈ~j | ||
@ | yS.C.2˜gzDBd—Ö@i1ƒTƒCƒNƒ‹–Új | ||
@ | yS.C.2˜gzDBd—Ö@i2`3ƒTƒCƒNƒ‹–Új | ||
@ | yS.C.2˜gzDBd—Ö@i4`8ƒTƒCƒNƒ‹–Új | ||
@ | yS.C.2˜gzDBd—Ö@i9ƒTƒCƒNƒ‹–ÚˆÈ~j | ||
@ | DCd—Ö@i2ƒTƒCƒNƒ‹–Új | ||
@ | DCd—Ö@i3`6ƒTƒCƒNƒ‹–Új | ||
@ | yS.C.2˜gzD-MPB—Ö@i2`9ƒTƒCƒNƒ‹–Új | ||
@ | yS.C.zDPd—Ö@i1ƒTƒCƒNƒ‹–Új | ||
@ | yS.C.zDPd—Ö@i2ƒTƒCƒNƒ‹–Új | ||
@ | yS.C.zDPd—Ö@i3-6ƒTƒCƒNƒ‹–Új | ||
@ | yS.C.zDPd—Ö@i7ƒTƒCƒNƒ‹–ÚˆÈ~j | ||
@ | y2˜gzIsaPd—Ö@i1ƒTƒCƒNƒ‹–Új | ||
@ | y2˜gzIsaPd—Ö@i2ƒTƒCƒNƒ‹–ÚˆÈ~j | ||
”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî | ƒŒƒWƒƒ“–¼ | ||
@ | y2˜gzR-CHOP—Ö@i1“úŠÔj | ||
@ | R+ƒxƒ“ƒ_ƒ€ƒXƒ`ƒ“i2“úŠÔj | ||
@ | R | ||
@ | G-Bend | ||
@ | R+ƒxƒ“ƒ_ƒ€ƒXƒ`ƒ“—Ö@ | ||
@ | G-Bend(1ƒTƒCƒNƒ‹) | ||
@ | G-Bend(‚QƒTƒCƒNƒ‹ˆÈ~) | ||
@ | ƒKƒUƒCƒo’P“ƈێ—Ö@ | ||
@ | y2˜gzR-THP-COPi70-79Îj(1“úŠÔj | ||
@ | y2˜gzR-THP-COPi80ΈÈãj(1“úŠÔj | ||
@ | R-CVPi1“úŠÔj | ||
@ | R-GCD | ||
@ | y2˜gzPola-BR—Ö@i2ƒTƒCƒNƒ‹–ÚˆÈ~j | ||
@ | y2˜gzPola-R-CHP—Ö@i2-6ƒTƒCƒNƒ‹–Új | ||
@ | yƒVƒ‡[ƒgzMTX-HOPE—Ö@ | ||
@ | A-CHP | ||
ƒzƒWƒLƒ“ƒŠƒ“ƒpŽî | ƒŒƒWƒƒ“–¼ | ||
@ | ABVD | ||
@ | A-AVD | ||
@ | y¼®°ÄzƒLƒCƒgƒ‹[ƒ_ | ||
‹}«œ‘«”’ŒŒ•a | ƒŒƒWƒƒ“–¼ | ||
@ | Ven{LDAC | ||
@ | Ven{AZA | ||
”ñ¬×–E”x‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | y¼®°ÄzALM | ||
@ | yƒVƒ‡[ƒgznab-PTX’P“Æ | ||
@ | yƒVƒ‡[ƒgzNSCLC-Durvalmab | ||
@ | yƒVƒ‡[ƒgzNSCLC-Nivolumab | ||
@ | CBDCA+nab-PTX 1, 8, 15 | ||
@ | Doc+Ram | ||
@ | non-sq: Pembro+CBDCA+ALM | ||
@ | NSCLC-Atezolizumab | ||
@ | NSCLC-Pembrolizumab | ||
@ | Sq: Pembro+CBDCA+nabPTC | ||
@ | yƒVƒ‡[ƒgzAtezo+BevˆÛŽ—Ã–@ | ||
@ | GEM+VNR@biweekly | ||
@ | NSCLC-Ipi-Nivo | ||
@ | yƒVƒ‡[ƒgzNSCLC-Nivolumab 4-week intervals | ||
@ | non-Sq: Pembro+ALMˆÛŽ—Ã–@ | ||
@ | NSCLC-Pembrolizumab 6-week intervals | ||
@ | VNR1C8 | ||
@ | y¼®°ÄzPEM | ||
@ | yƒVƒ‡[ƒgznab-PTX’P“Æ | ||
@ | yƒVƒ‡[ƒgzNSCLC-Durvalmab | ||
@ | yƒVƒ‡[ƒgzNSCLC-Nivolumab | ||
@ | CBDCA+nab-PTX 1, 8, 15 | ||
@ | Doc+Ram | ||
@ | non-sq: Pembro+CBDCA+ALM | ||
@ | NSCLC-Atezolizumab | ||
@ | NSCLC-Pembrolizumab | ||
@ | Sq: Pembro+CBDCA+nabPAC | ||
@ | yƒVƒ‡[ƒgzAtezo+BevˆÛŽ—Ã–@ | ||
@ | GEM+VNR@biweekly | ||
@ | NSCLC-Ipi-Nivo | ||
@ | yƒVƒ‡[ƒgzNSCLC-Nivolumab 4-week intervals | ||
@ | non-Sq: Pembro+ALMˆÛŽ—Ã–@ | ||
@ | NSCLC-Pembrolizumab 6-week intervals | ||
@ | VNR1C8 | ||
@ | Sq: PembroˆÛŽ—Ã–@ | ||
@ | y2˜gzCBDCA+PTX 1 | ||
@ | CBDCA+PTX 1C8C15 | ||
@ | DOC | ||
@ | y¼®°ÄzGEM@1C8 | ||
@ | yƒVƒ‡[ƒgzBViƒAƒoƒXƒ`ƒ“’P“Æj | ||
@ | non-Sq@Pembro+CBDCA+PEM | ||
@ | non-Sq: Pembro+PEMˆÛŽ—Ã–@ | ||
@ | y2˜gzAtezo+Bev+CBDCA+PAC | ||
@ | RAM+Erlotinib | ||
@ | y2˜gzAtezo+CBDCA+nab-PTX | ||
@ | CBDCA+TS-1 | ||
@ | y¼®°ÄzƒeƒZƒ“ƒgƒŠƒNpŒã•╉»Šw—Ö@ | ||
¬×–E”x‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | y2˜gzCDDP+CPT-11 1, 8, 15 | ||
@ | y2˜gzCBDCA+ETP1C2C3 | ||
@ | AMR@1C2C3 | ||
@ | SCLC-AtezoˆÛŽ—Ã–@ | ||
@ | CBDCA+ETP1C2C3 | ||
@ | SCLC-durvalumab-CBDCA-ETP | ||
@ | NGT | ||
@ | SCLC-maintenance-Durvalumab | ||
“ªèò•”‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | yƒVƒ‡[ƒgzƒIƒvƒW[ƒ{ | ||
@ | ƒpƒNƒŠƒ^ƒLƒZƒ‹+ƒZƒcƒLƒVƒ}ƒu@‰‰ñ | ||
@ | ƒpƒNƒŠƒ^ƒLƒZƒ‹+ƒZƒcƒLƒVƒ}ƒui2‰ñ–ÚˆÈ~j | ||
@ | y¼®°Äzƒyƒ€ƒuƒƒŠƒYƒ}ƒu | ||
@ | ƒA[ƒrƒ^ƒbƒNƒX’P“Æi2ƒR[ƒX–ÚˆÈ~j | ||
@ | yƒVƒ‡[ƒgzƒIƒvƒW[ƒ{(4TŠÔŠÔŠuj | ||
‘å’°‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | XELOXiƒ[ƒ[ƒ_+L-OHPj | ||
@ | ƒxƒNƒeƒBƒrƒbƒNƒXi6 mg/kgj+FOLFIRI | ||
@ | CPT-11+Pmab | ||
@ | FOLFIRI+ƒUƒ‹ƒgƒ‰ƒbƒv | ||
@ | FOLFIRI+ƒ‰ƒ€ƒVƒ‹ƒ}ƒu | ||
@ | FOLFOXIRI+Bev | ||
@ | UFT+LV+Bev | ||
@ | Weekly-Cetu+FOLFOX6iKRAS–ì¶Œ^j | ||
@ | ƒAƒoƒXƒ`ƒ“i10 mg/kgj+FOLFIRI | ||
@ | ƒAƒoƒXƒ`ƒ“i10 mg/kgj+mFOLFOX6 | ||
@ | ƒAƒoƒXƒ`ƒ“i5 mg/kgj+FOLFIRI | ||
@ | ƒAƒoƒXƒ`ƒ“i7.5 mg/kgj+XELOX | ||
@ | y2˜gzmFOLFOX6+Pmab | ||
@ | ƒA[ƒrƒ^ƒbƒNƒX’P“Æi2ƒR[ƒX–ÚˆÈ~j | ||
@ | mFOLFOX6 | ||
@ | ƒAƒoƒXƒ`ƒ“ (5mg/kg) + mFOLFOX6 | ||
@ | 5-FU+LV+BeviFOLFOXIRI+BevŒãˆÛŽ—Ã–@j | ||
@ | IRIS+ƒAƒoƒXƒ`ƒ“ (ƒAƒoƒXƒ`ƒ“+CPT11+TS-1 (SRIM ŽŽŒ±) | ||
@ | ƒxƒNƒeƒBƒrƒbƒNƒX@’P“Æ@i6mg/kgj | ||
@ | S-1+IRI+BEV ‚RTƒŒƒWƒƒ“ | ||
@ | SOX + ƒAƒoƒXƒ`ƒ“ (TS-1 + L-OHP + ƒAƒoƒXƒ`ƒ“) | ||
@ | w-ƒA[ƒrƒ^ƒbƒNƒX + bi- CPT-11 | ||
@ | y¼®°ÄzTAS102{BV | ||
@ | SOX (TS-1 + L-OHP ) | ||
@ | BEACON | ||
@ | ‘å’°Šà PER+HER | ||
@ | ƒƒ“ƒT[ƒt+Bev | ||
@ | JACCRO CC-13FFOLFOXIRI+Bev | ||
ˆÝ‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | iˆÝ‚ª‚ñ—pjSOXiTS-1+L-OHPj | ||
@ | iˆÝ‚ª‚ñ—pjXELOXiƒ[ƒ[ƒ_+L-OHP) | ||
@ | yƒVƒ‡[ƒgzGC-Nivolumab | ||
@ | CPT-11 ’P“Æ | ||
@ | SP+HERishort hydrationj | ||
@ | TS-1 + Docetaxel—Ö@ | ||
@ | weekly PTX+ƒ‰ƒ€ƒVƒ‹ƒ}ƒu | ||
@ | (ˆÝ‚ª‚ñ—pjmFOLFOX6 | ||
@ | y¼®°ÄzGC-Nivolumab (4w) | ||
@ | nab-PTX+RAM | ||
@ | FOLFOX{Nivo | ||
@ | SOX+HER | ||
@ | SOX{Nivo | ||
@ | weekly-PTX | ||
@ | XELOX{Nivo | ||
H“¹‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | iH“¹‚ª‚ñjweekly PTX | ||
@ | 3-weekly TXT | ||
@ | H“¹‚ª‚ñ-Nivolumab | ||
@ | H“¹‚ª‚ñ-Nivolumab (4w) | ||
@ | FP{Nivo(2T–ˆ) | ||
@ | y2˜gzFP{Pembro (6ƒR[ƒX‚Ü‚Å) | ||
@ | y¼®°ÄzH“¹Šà]Nivolumabi2wjipŒã•â•j | ||
@ | y¼®°ÄzH“¹Šà]Nivolumabi4wjipŒã•â•j | ||
@ | IPI{Nivo(2T–ˆ) | ||
@ | IPI{Nivo(3T–ˆ) | ||
@ | @ | @ | @ |
äX‘Ÿ‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | y¼®°ÄzGEM’P“Æ (Ž¡—×p) | ||
@ | FOFIRINOX | ||
@ | nab-PTX+GEM | ||
@ | y2˜gzNal-IRI+5-FU/LV | ||
@ | GEM’P“Æ (Ž¡—×p) | ||
@ | GEM 1, 8 + TS-1 (2“Š1‹x)@(Ž¡—×p) | ||
@ | @ | @ | @ |
’_“¹‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | y2˜gzGEM‡@‡G+CDDP‡@‡G | ||
@ | GCS—Ö@ | ||
@ | y2˜gzDurvalumab+GEM+CDDP—Ö@ | ||
@ | @ | ||
ŠÌ‘Ÿ‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | ƒ‰ƒ€ƒVƒ‹ƒ}ƒu’PÜ | ||
@ | Atezo+Bmab | ||
“û‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | 3wk HER | ||
@ | GEM@1C8 | ||
@ | CMFyp.o.ziCPA+MTX+5-FUj | ||
@ | DOC100 | ||
@ | Doc75+PER+HER | ||
@ | EC80iEPI+CPAj | ||
@ | FEC100i5-FU+EPI+CPAj | ||
@ | PTX+PER{HER | ||
@ | TC—Ö@yivziTXT+CPAyivzj | ||
@ | wPTX (12wk) | ||
@ | wPTX+ƒxƒoƒVƒYƒ}ƒu | ||
@ | ƒGƒŠƒuƒŠƒ“ | ||
@ | ´ØÌÞØÝ+PER+HER | ||
@ | ƒJƒhƒTƒCƒ‰ | ||
@ | y¼®°Äz2w VNR | ||
@ | ƒGƒ“ƒn[ƒc | ||
@ | GEM+PER{HER (2ƒR[ƒX–ÚˆÈ~) | ||
@ | Pembro{CG | ||
@ | Pembro{EC (NAC2) | ||
@ | Pembro{wPTX{wCBDCA (NAC1) | ||
@ | VNR 1C8 | ||
@ | y¼®°Äz3wABX (ƒAƒuƒ‰ƒLƒTƒ“) | ||
@ | XT —Ö@ (DOC60+Xeloda) | ||
@ | GEM+CBDCA | ||
@ | ´ØÌÞØÝ+PER+HER(‚QƒR[ƒX–ÚˆÈ~) | ||
@ | VNR+PER{HER (2ƒR[ƒX–ÚˆÈ~) | ||
”]Žîᇠ| ƒŒƒWƒƒ“–¼ | ||
@ | yƒVƒ‡[ƒgzƒAƒoƒXƒ`ƒ“’P“Æ | ||
t‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | yƒVƒ‡[ƒgzƒeƒ€ƒVƒƒŠƒ€ƒX—Ö@ | ||
@ | yƒVƒ‡[ƒgzƒjƒ{ƒ‹ƒ}ƒu—Ö@it‚ª‚ñj | ||
@ | tŠàƒjƒ{ƒ‹ƒ}ƒu+ƒCƒsƒŠƒ€ƒ}ƒu@ʼn4ƒR[ƒX | ||
@ | ƒAƒxƒ‹ƒ}ƒu{ƒAƒLƒVƒ`ƒjƒu•¹—p—Ö@ | ||
@ | ÆÎÞÙÏÌޗÖ@ 4TŠÔ»²¸ÙitŠà 2nd linej | ||
@ | tŠà ÍßÑÌÞÛØ½ÏÌÞ6TŠÔ{±·¼ÁÆÌÞ•¹—p—Ö@ | ||
@ | ²ËßEÆÎÞŒã ÆÎÞÙÏÌÞ’PޗÖ@ 4w»²¸ÙitŠà j | ||
@ | y¼®°Äzƒjƒ{ƒ‹ƒ}ƒu{ƒJƒ{ƒUƒ“ƒ`ƒjƒu•¹—p—Ö@ | ||
@ | y¼®°Äzƒjƒ{ƒ‹ƒ}ƒu4TŠÔ{ƒJƒ{ƒUƒ“ƒ`ƒjƒu•¹—p—Ö@ | ||
@ | y¼®°Äzt×–EŠà ÍßÝÌÞÛØ½ÞÏÌÞ3T{ÚÝÊÞÁÆÌÞ•¹—p—Ö@ | ||
@ | y¼®°Äzt×–EŠà ÍßÝÌÞÛØ½ÞÏÌÞ6T{ÚÝÊÞÁÆÌÞ•¹—p—Ö@ | ||
äNã÷‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | GEM+CBDCA—Ö@ | ||
@ | UC-Pembrolizumab | ||
@ | ”A˜Hã”çŠà ÍßÑÌÞÛØ½ÏÌޗÖ@ 6TŠÔ»²¸Ù | ||
@ | ”A˜Hã”çŠà ƒpƒhƒZƒu—Ö@ | ||
@ | ”A˜Hã”çŠà ƒAƒxƒ‹ƒ}ƒuˆÛŽ—Ã–@ | ||
@ | (‰ü’ù”Å)GC | ||
@ | GEM+CBDCA—Ö@(30<CCr<60 CDDP•s‰ÂÇ—áj | ||
@ | y¼®°ÄzUCpŒãƒjƒ{ƒ‹ƒ}ƒu—Ö@ 2TŠÔƒTƒCƒNƒ‹ | ||
@ | y¼®°ÄzUCpŒãƒjƒ{ƒ‹ƒ}ƒu—Ö@ 4TŠÔƒTƒCƒNƒ‹ | ||
‘O—§‘B‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | Cabazitaxel—Ö@ | ||
@ | Triweekly DOC | ||
ˆ««•FŽî | ƒŒƒWƒƒ“–¼ | ||
@ | yƒVƒ‡[ƒgzMM biwekly Nivolumab | ||
@ | MM Nivolumab adjuvant 4W | ||
@ | MM@Pembrolizumab | ||
@ | MM Nivolumab 4W | ||
@ | Nivolumab+Ipilimumab | ||
@ | yƒVƒ‡[ƒgzMM-ƒyƒ“ƒuƒƒŠƒYƒ}ƒu@400‡r | ||
@ | y¼®°ÄzMM Nivolumab 4W | ||
—‘‘ƒ‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | y2˜gzPTX+CBDCA | ||
@ | y2˜gzPTX+CBDCA+Bev | ||
@ | yƒVƒ‡[ƒgzGEM’P“Ƈ@‡G‡N | ||
@ | DOC+CBDCA | ||
@ | PLD+Bev | ||
@ | CPT-11+CDDP | ||
@ | PLD+CBDCA | ||
@ | dd-PTX ‡@ ‡G ‡N + CBDCA ‡@ | ||
@ | BEP—Ö@ | ||
@ | BevÒÝÃÅݽ | ||
@ | weeklyPTX+Bev | ||
@ | DOC+CBDCA+Bev | ||
@ | NGT | ||
Žq‹{‘Ì‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | AP—Ö@ | ||
@ | PTX+CBDCA | ||
@ | y¼®°ÄzƒŒƒ“ƒrƒ}+ƒLƒCƒgƒ‹[ƒ_(200mg q3w) | ||
@ | DP—Ö@ | ||
Žq‹{èò‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | y2˜gz‚b‚o‚s|11+‚m‚c‚o | ||
@ | TC-Bev | ||
@ | CPT-11’P“Æ ‡@ ‡G ‡N | ||
@ | y2˜gzPem+TCBev | ||
@ | Pem+BevˆÛŽ—Ã–@ | ||
ŒÅŒ`‚ª‚ñ | ƒŒƒWƒƒ“–¼ | ||
@ | MSI-High@pembro | ||
@ | y¼®°ÄzTMB-High 3T Pembro | ||
ƒAƒ~ƒƒCƒh[ƒVƒX | ƒŒƒWƒƒ“–¼ | ||
@ | yS.CzDCyBorD—Ö@i1ƒTƒCƒNƒ‹–Új | ||
@ | yS.CzDCyBorD—Ö@i2ƒTƒCƒNƒ‹–Új | ||
@ | yS.CzDCyBorD—Ö@i3-6ƒTƒCƒNƒ‹–Új | ||
@ | yS.CzDCyBorD—Ö@i7ƒTƒCƒNƒ‹–ÚˆÈ~j | ||
‹}«TƒŠƒ“ƒp«”’ŒŒ•a | ƒŒƒWƒƒ“–¼ | ||
@ | ƒ|ƒeƒŠƒWƒI’P“Æ | ||
“÷Žî | ƒŒƒWƒƒ“–¼ | ||
@ | y¼®°ÄzƒGƒŠƒuƒŠƒ“ | ||
@ | DXR | ||
Œ´”•s–¾Šà | ƒŒƒWƒƒ“–¼ | ||
@ | y¼®°ÄzNivo@CUP@240mg q2w | ||